Sandbox/20: Difference between revisions

Jump to navigation Jump to search
Line 15: Line 15:
|style="width:35%"|'''Alternative Regimen'''
|style="width:35%"|'''Alternative Regimen'''
|-
|-
| '''''Preterm—1 mo''''' || '''''[[Streptococcus agalactiae]]''''' (49%) <BR> '''''[[Escherichia coli]]''''' (18%) <BR> '''''misc. Gram-positive''''' (10%) <BR>  '''''misc. Gram-negative''''' (10%) <BR> '''''[[Listeria]]''''' (7%) || '''''Drug A''''' <BR> ''PLUS'' <BR> '''''Drug B''''' || '''''Drug C''''' <BR> ''PLUS'' <BR> '''''Drug D'''''
| '''''Preterm—1 mo''''' || '''''[[Streptococcus agalactiae]]''''' (49%) <BR> '''''[[Escherichia coli]]''''' (18%) <BR> '''''misc. Gram-positive''''' (10%) <BR>  '''''misc. Gram-negative''''' (10%) <BR> '''''[[Listeria]]''''' (7%) || '''''[[Ampicillin]]''''' <BR> ''PLUS'' <BR> '''''[[Cefotaxime]]''''' <BR> (for dosage see footnote) || '''''[[Ampicillin ]]''''' <BR> ''PLUS'' <BR> '''''[[Gentamicin]]''''' <BR>(for dosage see footnote)
|-
|-
| '''''1 mo—50 yrs''''' || '''''[[Streptococcus pneumoniae]] <BR> [[Neisseria meningitidis]] <BR> [[Haemophilus influenzae]]<sup>†</sup> || '''''[[Cefotaxime]] 2 gm IV q4—6h''''' ''OR'' '''''[[Ceftriaxone]] 2 gm IV q12h''''' <BR> ''PLUS'' <BR> '''''[[Vancomycin]] 500—750 mg IV q6h'''''<sup>‡</sup> <BR> ''PLUS'' <BR> '''''[[Dexamethasone]]''''' ||  
| '''''1 mo—50 yrs''''' || '''''[[Streptococcus pneumoniae]] <BR> [[Neisseria meningitidis]] <BR> [[Haemophilus influenzae]]<sup>†</sup> ||'''''Adult dosage:'''''[[Cefotaxime]] 2 gm IV q4—6h''''' ''OR'' '''''[[Ceftriaxone]] 2 gm IV q12h''''' <BR> ''PLUS'' <BR> '''''[[Vancomycin]] 500—750 mg IV q6h'''''<sup>‡</sup> <BR> ''PLUS'' <BR> '''''[[Dexamethasone]]''''' ''<BR> ''''''Peds:''''''[[Cefotaxime]]''''' 200 mg/kg per day IV div. q6–8h; [[Ceftriaxone]] 100 mg/kg per day IV div. q12h; [[Vancomycin]] 15 mg/kg IV q6h.||'''''  [[Meropenem]]2 gm IV q8h''''' <BR> ''PLUS'' <BR>'''''[[Vancomycin]]''''' <BR> ''PLUS'' <BR>'''''IV [[Dexamethasone ]]
|-
|-
| '''''1.>50 yrs 2.alcoholism 3.debilitating assoc diseases 4.impaired cellular immunity''''' || 123 || 123 || 123
| '''''1.>50 yrs 2.alcoholism 3.debilitating assoc diseases 4.impaired cellular immunity''''' || '''''[[Streptococcus pneumoniae ]]'''''<BR>'''''[[listeria]]'''''[[Gram-negative|Gram-negative bacilli]]''''' ||'''''[[Ampicillin]] 2 gm IV q4h ''''' <BR> ''PLUS''<BR>''''''[[Ceftriaxone]] 2 gm IV q12h''''' OR '''''[[Cefotaxime]] 2 gm IV q6h''''' <BR> ''PLUS'' <BR> '''''[[Vancomycin]]'''''<BR> ''PLUS'' <BR>'''''IV [[Dexamethasone ]]'''''
|| '''''[[Meropenem]] 2 gm IV q8h''''' <BR> ''PLUS''<BR> '''''[[Vancomycin]]''''' <BR> ''PLUS'' <BR> IV '''''[[Dexamethasone ]]'''''
|-
| '''''Post-neurosurgery, post-head trauma, or post-cochlear implant || '''''[[Streptococcus pneumoniae]] most common, esp. if CSF leak.'''''<BR>Other: [[Staphylococcus aureus]], coliforms, [[Pseudomonas aeruginosa]]||'''''Vancomycin (until known not MRSA) 500–750 mg IV q6h2''''''<BR> ''PLUS'' <BR> '''''[[Cefepime]] or [[Ceftazidime]] 2 gm IV q8h'''''||'''''[[Meropenem]] 2 gm IV q8h'''''<BR> ''PLUS'' <BR> '''''[[Vancomycin]]1 gm IV q6–12h '''''
|-
| Ventriculitis/meningitis due to infected ventriculo-peritoneal (atrial) shunt||'''''[[Staphylococcus epidermidis]],'''''[[Staphylococcus aureus]],'''''coliforms,diphtheroids (rare),''''''[[Propionibacterium acnes]]'''''||'''''[[Vancomycin]] 500–750 mg IV q6h '''''<BR> ''PLUS''<BR> '''''[[cefepime]]''''' ''or'' '''''[[ceftazidime]] 2 gm IV q8h'''''||'''''[[Vancomycin]]''''' 500–750 mg IV q6h''''' <BR> ''PLUS'' <BR>'''''[[Meropenem]]''''' 2 gm IV q8h '''''
|-
|-
|}
|}


<sup>†</sup> H. influenzae now very rare, listeria unlikely if young & immuno-competent (add ampicillin if suspect listeria: 2 gm IV q4h)
<sup>†</sup> H. influenzae now very rare, listeria unlikely if young & immuno-competent (add ampicillin if suspect listeria: 2 gm IV q4h)


<sup>‡</sup> Children’s dosage 15 mg/kg IV q6h (2x standard adult dose)
<sup>‡</sup> Children’s dosage 15 mg/kg IV q6h (2x standard adult dose). In adults, max dose of 2-3 gm/day is suggested: 500–750 mg IV q6h.
====Postive CSF Gram Stain====
{| class="wikitable" border="1" style="background:Snow; font-size:85%;"
|-
|style="width:10%"|'''Group'''
|style="width:20%"|'''Etiology'''
|style="width:35%"|'''Preferred Regimen'''
|style="width:35%"|'''Alternative Regimen'''
|-
| '''''Gram-positive diplococci''''' || '''''[[S.pneumoniae]]''''' ||'''''[[Ceftriaxone]] 2 gm IV q12h''''' ''OR'' ''''' [[Cefotaxime]] 2 gm IV q4–6h''''' <BR> ''PLUS'' <BR> '''''[[Vancomycin]] 500–750 mg IV q6h''''' <BR> ''PLUS'' <BR> '''''timed [[Dexamethasone]] 0.15 mg/kg q6h IV x 2–4 days || '''''[[Meropenem]] 2 gm IV q8h''''' ''OR'' '''''[[Moxifloxacin]] 400 mg IV q24h'''''
|-
| '''''Gram-negative diplococci ''''' || '''''[[N. meningitidis]]'''''||'''''[[Cefotaxime]] 2 gm IV q4–6h''''' ''OR'' '''''[[Ceftriaxone]] 2 gm IV q12h'''''||'''''[[Penicillin G]] 4 mill. units IV q4h''''' ''OR'' '''''[[Ampicillin]] 2 gm q4h''''' ''OR'' '''''[[Moxifloxacin]] 400 mg IV
q24h''''' ''OR'' '''''[[Chloro]] 1 gm IV q6h'''''
|-
| '''''1.>50 yrs 2.alcoholism 3.debilitating assoc diseases 4.impaired cellular immunity''''' || '''''[[Streptococcus pneumoniae]]'''''<BR>'''''[[listeria]]'''''[[Gram-negative|Gram-negative bacilli]]''''' ||'''''[[Ampicillin]] 2 gm IV q4h ''''' <BR>''PLUS''<BR>''''''[[Ceftriaxone]] 2 gm IV q12h''''' OR '''''[[Cefotaxime]] 2 gm IV q6h''''' <BR> ''PLUS'' <BR> '''''[[Vancomycin]]'''''<BR> ''PLUS''<BR>'''''IV [[Dexamethasone ]]'''''
|| '''''[[Meropenem]] 2 gm IV q8h''''' <BR> ''PLUS''<BR> '''''[[Vancomycin]]''''' <BR> ''PLUS'' <BR> IV '''''[[Dexamethasone ]]'''''
|-
| '''''Post-neurosurgery, post-head trauma, or post-cochlear implant || '''''[[Streptococcus pneumoniae]] most common, esp. if CSF leak.'''''<BR>Other:[[Staphylococcus aureus]], coliforms, [[Pseudomonas aeruginosa]]||'''''Vancomycin (until known not MRSA) 500–750 mg IV q6h2''''''<BR> ''PLUS'' <BR>'''''[[Cefepime]] or [[Ceftazidime]] 2 gm IV q8h'''''||'''''[[Meropenem]] 2 gm IV q8h'''''<BR> ''PLUS'' <BR> '''''[[Vancomycin]]1 gm IV q6–12h '''''
|-
| Ventriculitis/meningitis due to infected ventriculo-peritoneal (atrial) shunt||'''''[[Staphylococcus epidermidis]],'''''[[Staphylococcus aureus]],'''''coliforms,diphtheroids (rare),''''''[[Propionibacterium acnes]]'''''||'''''[[Vancomycin]] 500–750 mg IV q6h '''''<BR> ''PLUS''<BR>'''''[[cefepime]]''''' ''or'' '''''[[ceftazidime]] 2 gm IV q8h'''''||'''''[[Vancomycin]]''''' 500–750 mg IV q6h''''' <BR> ''PLUS''<BR>'''''[[Meropenem]]''''' 2 gm IV q8h '''''
|-
|}


====Positive CSF Gram Stain====
====Positive CSF Gram Stain====

Revision as of 04:24, 16 December 2013

Bacterial Meningitis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Diagnosis

Empiric Therapy

Negative CSF Gram Stain

Group Etiology Preferred Regimen Alternative Regimen
Preterm—1 mo Streptococcus agalactiae (49%)
Escherichia coli (18%)
misc. Gram-positive (10%)
misc. Gram-negative (10%)
Listeria (7%)
Ampicillin
PLUS
Cefotaxime
(for dosage see footnote)
Ampicillin
PLUS
Gentamicin
(for dosage see footnote)
1 mo—50 yrs Streptococcus pneumoniae
Neisseria meningitidis
Haemophilus influenzae
Adult dosage:Cefotaxime 2 gm IV q4—6h OR Ceftriaxone 2 gm IV q12h
PLUS
Vancomycin 500—750 mg IV q6h
PLUS
Dexamethasone
'
Peds:'Cefotaxime 200 mg/kg per day IV div. q6–8h; Ceftriaxone 100 mg/kg per day IV div. q12h; Vancomycin 15 mg/kg IV q6h.
Meropenem2 gm IV q8h
PLUS
Vancomycin
PLUS
IV Dexamethasone
1.>50 yrs 2.alcoholism 3.debilitating assoc diseases 4.impaired cellular immunity Streptococcus pneumoniae
listeriaGram-negative bacilli
Ampicillin 2 gm IV q4h
PLUS
'Ceftriaxone 2 gm IV q12h OR Cefotaxime 2 gm IV q6h
PLUS
Vancomycin
PLUS
IV Dexamethasone
Meropenem 2 gm IV q8h
PLUS
Vancomycin
PLUS
IV Dexamethasone
Post-neurosurgery, post-head trauma, or post-cochlear implant Streptococcus pneumoniae most common, esp. if CSF leak.
Other: Staphylococcus aureus, coliforms, Pseudomonas aeruginosa
Vancomycin (until known not MRSA) 500–750 mg IV q6h2'
PLUS
Cefepime or Ceftazidime 2 gm IV q8h
Meropenem 2 gm IV q8h
PLUS
Vancomycin1 gm IV q6–12h
Ventriculitis/meningitis due to infected ventriculo-peritoneal (atrial) shunt Staphylococcus epidermidis,Staphylococcus aureus,coliforms,diphtheroids (rare),'Propionibacterium acnes Vancomycin 500–750 mg IV q6h
PLUS
cefepime or ceftazidime 2 gm IV q8h
Vancomycin 500–750 mg IV q6h
PLUS
Meropenem 2 gm IV q8h

H. influenzae now very rare, listeria unlikely if young & immuno-competent (add ampicillin if suspect listeria: 2 gm IV q4h)

Children’s dosage 15 mg/kg IV q6h (2x standard adult dose). In adults, max dose of 2-3 gm/day is suggested: 500–750 mg IV q6h.

Postive CSF Gram Stain

Group Etiology Preferred Regimen Alternative Regimen
Gram-positive diplococci S.pneumoniae Ceftriaxone 2 gm IV q12h OR Cefotaxime 2 gm IV q4–6h
PLUS
Vancomycin 500–750 mg IV q6h
PLUS
timed Dexamethasone 0.15 mg/kg q6h IV x 2–4 days
Meropenem 2 gm IV q8h OR Moxifloxacin 400 mg IV q24h
Gram-negative diplococci N. meningitidis Cefotaxime 2 gm IV q4–6h OR Ceftriaxone 2 gm IV q12h Penicillin G 4 mill. units IV q4h OR Ampicillin 2 gm q4h OR Moxifloxacin 400 mg IV

q24h OR Chloro 1 gm IV q6h

1.>50 yrs 2.alcoholism 3.debilitating assoc diseases 4.impaired cellular immunity Streptococcus pneumoniae
listeriaGram-negative bacilli
Ampicillin 2 gm IV q4h
PLUS
'Ceftriaxone 2 gm IV q12h OR Cefotaxime 2 gm IV q6h
PLUS
Vancomycin
PLUS
IV Dexamethasone
Meropenem 2 gm IV q8h
PLUS
Vancomycin
PLUS
IV Dexamethasone
Post-neurosurgery, post-head trauma, or post-cochlear implant Streptococcus pneumoniae most common, esp. if CSF leak.
Other:Staphylococcus aureus, coliforms, Pseudomonas aeruginosa
Vancomycin (until known not MRSA) 500–750 mg IV q6h2'
PLUS
Cefepime or Ceftazidime 2 gm IV q8h
Meropenem 2 gm IV q8h
PLUS
Vancomycin1 gm IV q6–12h
Ventriculitis/meningitis due to infected ventriculo-peritoneal (atrial) shunt Staphylococcus epidermidis,Staphylococcus aureus,coliforms,diphtheroids (rare),'Propionibacterium acnes Vancomycin 500–750 mg IV q6h
PLUS
cefepime or ceftazidime 2 gm IV q8h
Vancomycin 500–750 mg IV q6h
PLUS
Meropenem 2 gm IV q8h

Positive CSF Gram Stain

Pathogen-Specific Therapy

Do's

Don'ts

References


Template:WikiDoc Sources